Recombinant multi-species FREM1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine FREM1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a basement membrane protein that may play a role in craniofacial and renal development. Mutations in this gene have been associated with bifid nose with or without anorectal and renal anomalies. Alternatively spliced transcript variants encoding different isoforms have been described. PubMed ID 19940113 describes one such variant that initiates transcription within a distinct, internal exon; the resulting shorter isoform (named Toll-like/interleukin-1 receptor regulator, TILRR) is suggested to be a co-receptor of the interleukin 1 receptor family and may regulate receptor function and Toll-like receptor/interleukin 1 receptor signal transduction, contributing to the control of inflammatory response activation. [provided by RefSeq, Apr 2011]
The Alternative Names of target: BNAR,C9orf143,C9orf145,C9orf154,D430009N09,D630008K06,FRAS1-related extracellular matrix protein 1,FREM1,Frem1,MOTA,Protein QBRICK,RGD1306981,TILRR,TRIGNO2,crf11,eye,eyes2,heb,qbrick

Target products collectionGo to FREM1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0224-Ag-1/ GM-Tg-hg-SE0224-Ag-2 Human FREM1 protein Human
GM-Tg-rg-SE0224-Ag-1/ GM-Tg-rg-SE0224-Ag-2 Rat FREM1 protein Rat
GM-Tg-mg-SE0224-Ag-1/ GM-Tg-mg-SE0224-Ag-2 Mouse FREM1 protein Mouse
GM-Tg-cynog-SE0224-Ag-1/ GM-Tg-cynog-SE0224-Ag-2 Cynomolgus/Rhesus macaque FREM1 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0224-Ag-1/ GM-Tg-felg-SE0224-Ag-2 Feline FREM1 protein Feline
GM-Tg-cang-SE0224-Ag-1/ GM-Tg-cang-SE0224-Ag-2 Canine FREM1 protein Canine
GM-Tg-bovg-SE0224-Ag-1/ GM-Tg-bovg-SE0224-Ag-2 Bovine FREM1 protein Bovine
GM-Tg-equg-SE0224-Ag-1/ GM-Tg-equg-SE0224-Ag-2 Equine FREM1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0224-Ag-1/ GM-Tg-hg-SE0224-Ag-2; GM-Tg-rg-SE0224-Ag-1/ GM-Tg-rg-SE0224-Ag-2;
GM-Tg-mg-SE0224-Ag-1/ GM-Tg-mg-SE0224-Ag-2; GM-Tg-cynog-SE0224-Ag-1/ GM-Tg-cynog-SE0224-Ag-2;
GM-Tg-felg-SE0224-Ag-1/ GM-Tg-felg-SE0224-Ag-2; GM-Tg-cang-SE0224-Ag-1/ GM-Tg-cang-SE0224-Ag-2;
GM-Tg-bovg-SE0224-Ag-1/ GM-Tg-bovg-SE0224-Ag-2; GM-Tg-equg-SE0224-Ag-1/ GM-Tg-equg-SE0224-Ag-2
Products Name FREM1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name FREM1
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine FREM1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.